Clinical Trial Update: Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial comparing sorafenib to TransArterial Chemoembolization plus radiotherapy in hepatocellular carcinoma with macrovascular invasion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• TransArterial Chemoembolization plus Radiotherapy

Snippet

Sponsor: Asan Medical Center | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: COMPLETED